Various new data on Genentech’s Actemra (tocilizumab) and Rituxan (rituximab) will be presented at the 2017 European League Against Rheumatism (EULAR) annual congress in Madrid, June 14-17. The data highlight the continued safety and efficacy of both Actemra and Rituxan in patients with rheumatic diseases and vasculitis, as well as unmet needs in lupus nephritis.

Genentech continues to study treatments for autoimmune diseases with significant unmet medical need. The company is conducting a Phase III clinical study, called focuSSced (NCT02453256), investigating the use of Actemra in patients with systemic sclerosis. Additionally, Genentech is currently enrolling sites and patients in a Phase II clinical trial called NOBILITY (NCT02550652) to study obinutuzimab, a CD20-directed cytolytic antibody, in adults with lupus nephritis.

Recently, U.S. FDA granted breakthrough therapy designation to Rituxan in pemphigus vulgaris, a rare, serious and life-threatening condition, and approved Actemra for the treatment of giant cell arteritis (GCA), a chronic and severe autoimmune condition. At EULAR, the pivotal Phase III GiACTA data that led to Actemra’s approval for GCA will be presented for the first time at a rheumatology congress outside of the United States.

Below is an agenda and description of what their innovate presentation will cover:

Actemra Data: Optimal Dose of Tocilizumab for the Treatment of Giant Cell Arteritis: Efficacy, Safety, and Exposure-Efficacy Analysis from Giacta

(Thursday, June 15th at 10:30am, South Auditorium) (Oral Presentation) (OP0131)

  • Presenter: Dr. John Stone
  • The compelling treatment effect of Actemra in giant cell arteritis (GCA) patients as measured by sustained remission to 52 weeks was consistent regardless of disease-onset status. Duration of relapse-free remission until flare was longer in patients with higher Actemra exposure, most notable in relapsing patients treated with Actemra-QW.
  • This will be the first presentation of GiACTA at a rheumatology congress outside of the U.S.
  • The GiACTA data led to Actemra becoming the first and only FDA-approved treatment for GCA

 

Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations

(Thurdsay, June 15th at 11:30am, Hall 8) (Oral Presentation) (OP0105)

  • Presenter: Shalini Mohan, MD, Genentech
  • The safety profile of Actemra in the current analysis, which includes information about safety events from 12 clinical trials and their LTEs and across seven years of real-world postmarketing reports encompassing ≈ 600,000 patients, was consistent with previous safety reports. These findings are consistent with the previously reported profile of Actemra and indicate that there is no evidence of increased safety risk with increasing exposure to Actemra. 

 

Evaluation of a Dosing Regimen for Tocilzumab in Patients Younger than Two Years of Age with Systemic Juvenile Idiopathic Arthritis 

(Thursday, June 15th at 2:35pm, North Convention Center) (Oral Presentation) (OP0197)

  • Presenter: Navita L. Mallalieu, Clinical Director, Roche
  • This study provides evidence that Actemra is effective in sJIA pts <2 years of age, achieves PK and efficacy similar to those demonstrated previously in older pts, and has a similar AE safety profile, but there was a higher incidence of serious hypersensitivity events and suspected MAS.

 

Sustained Response Following Discontinuation of Methotrexate in Patients with RA with Sub-Q Tocilizumab, Results from a Randomized Controlled Trial (Comp-Act) 

(Friday, June 16th at 11:30am, Poster Area) (Poster Tour) (FRI0222)

  • Presenter: Joel Kremer, Albany Medical College and The Center for Rheumatology
  • The results in this study demonstrated that patients receiving Actemra-COMBO who achieve low disease activity can continue MTX and maintain disease control. 

 

Clinical Remission in subjects with RA treated with Sub-Q Tocilizumab as Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: a Real World Clinical Trial.

(Saturday, June 17th at 10:15am, Poster Area) (Poster Tour) (SAT0183)

  • Presenter: Raimon Sanmarti, Hospital Clinic, Barcelona, Spain
  • In the real world setting, treatment with Actemra-SC 162 mg weekly in patients with active RA is associated with sustained clinical remission of approximately 50 percent regardless it is administered as monotherapy or in combination with a sDMARD. The safety profile of Actemra-SC was consistent with previous studies of Actemra-SC and Actemra-IV.

Actemra/Rituxan Data:

Comparative Effectiveness of Abatcept, Rituximab, Tocilzumab and TFN1 Biological Dmards in RA: Results from the Nationwide Swedish Register. 

(Friday, June 16th, All Day, Poster Area) (Poster Tour) (FRI0213)

  • Presenter: Thomas Frisell, Karolinska Institutet, Stockholm, Sweden
  • Despite channeling of older and sicker individuals to non-TNFi-bDMARDs, treatment outcomes were in general better in these groups, particularly for Actemra and Rituxan.

Rituxan Data:

Safety Following Initiation of Rituximab in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Interm Analysis of the Rituximab in ANCA-Associated Vasculitis Registry (Raver) 

(Thursday, June 15th at 1:00pm, Poster Area) (THU0301)

  • Presenter: Dr. John Niles, Massachusetts General Hospital, Boston, MA
  • In patients with GPA/MPA treated with Rituxan, SAEs were not increased compared with comparable cohorts of patients with renal involvement. Safety events did not increase with Rituxan treatment. These results are consistent with the known safety profile of Rituxan and provide preliminary long-term, practice-level safety data for Rituxan in GPA/MPA.

 

Repeated Rituximab Infusions for the Therapy of RA is not Associated with Increased Rates of Serious Infections 

(Saturday, June 17th, All Day, Poster Area) (Poster Tour) (SAT0196)

  • Presenter: Dimitrios A. Pappas, Columbia University, Corrona LLC
  • Retreatment with Rituxan infusions was not associated with a higher rate of SIEs in this study. Patients who experienced an SIE had a higher prevalence of risk factors for infections. 

Lupus Nephritis Data:

FRI0285: Lupus Nephritis is Associated with INcreased Rates of Hospitalization an In-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data. 

(Friday, June 16th, All Day, Poster Area) (Poster Tour) (FRI0285)

  • Presenter: Katherine Belendiuk, Research Scientist, Genentech
  • A systemic lupus erythematosus diagnosis was associated with a higher burden of comorbidities and higher rates of hospitalizations and in-hospital mortality than patients without an autoimmune condition. Patients with lupus nephritis had the highest burden of comorbidities and rates of hospitalizations and in-hospital mortality.

 

56 thoughts on “Genentech to Highlight Actemra and Rituxan Data at EULAR Annual Congress”

  1. It’s enormous that you are getting thoughts from this piece
    of writing as well as from our argument made at this place.

  2. Thanks on your marvelous posting! I seriously enjoyed reading
    it, you happen to be a great author.I will make sure to bookmark
    your blog and may come back later on. I want to encourage yourself to continue your great posts, have a nice morning!

  3. Thanks for sharing your thoughts on ps4 free
    games. Regards

  4. Valuable info. Lucky me I discovered your website by accident, and I’m shocked why this
    coincidence didn’t took place earlier! I bookmarked it.

  5. Excellent way of telling, and good piece of writing to take facts regarding my presentation topic, which i am going to convey in university.

  6. I’m really loving the theme/design of your web site. Do you ever run into any browser compatibility issues?
    A few of my blog audience have complained about my site not working correctly in Explorer but looks great in Firefox.
    Do you have any tips to help fix this issue?

  7. Hey I know this is off topic but I was wondering if you knew of any widgets
    I could add to my blog that automatically tweet my newest twitter updates.
    I’ve been looking for a plug-in like this for quite some time and was hoping maybe you would have some experience with something like this.
    Please let me know if you run into anything.

    I truly enjoy reading your blog and I look forward to your new updates.

  8. quest bars says:

    Hello, after reading this remarkable paragraph i am as well delighted to share
    my experience here with friends.

  9. My relatives every time say that I am wasting my time here at net, except I know I am
    getting familiarity every day by reading thes fastidious articles.

  10. Quality articles or reviews is the crucial to invite the visitors to
    pay a quick visit the site, that’s what this web page is
    providing.

  11. First of all I would like to say great blog! I had a quick
    question in which I’d like to ask if you do not mind. I was curious to know how you center yourself
    and clear your mind prior to writing. I’ve had difficulty clearing my mind
    in getting my thoughts out there. I do enjoy writing however it just seems like the first 10 to 15 minutes tend to be lost just trying
    to figure out how to begin. Any ideas or hints? Thank you!

  12. Thanks for another wonderful article. Where else may just anyone get
    that type of information in such an ideal manner of writing?
    I’ve a presentation next week, and I’m on the look for such information.

  13. Hello, i read your blog occasionally and i own a similar one and i was just curious if you get a lot of spam responses? If so how do you stop it, any plugin or anything you can recommend? I get so much lately it’s driving me mad so any support is very much appreciated.

  14. I used to be suggested this web site by means of my cousin. I am now not sure whether this publish is written through him as no one else
    recognise such unique about my problem. You are
    amazing! Thank you!

  15. You really make it seem so easy with your presentation but I find this matter to be really something which I think I would never understand.
    It seems too complex and very broad for me. I am looking forward for your next post,
    I will try to get the hang of it!

  16. Good day! I simply would like to offer you a huge thumbs up for your great information you’ve got here
    on this post. I will be returning to your blog for more soon.

  17. Good post. I learn something new and challenging on blogs I stumbleupon everyday.
    It’s always exciting to read through articles from other authors and practice a little something from other websites.

  18. Sweet blog! I found it while surfing around on Yahoo News.
    Do you have any tips on how to get listed in Yahoo News?
    I’ve been trying for a while but I never seem to get there!
    Many thanks

  19. I all the time used to read post in news papers but now as I am a user of internet therefore from now I am using net for articles, thanks to web.

  20. I am actually glad to glance at this blog posts which
    carries tons of helpful data, thanks for providing these kinds of information.

  21. Exceptional post but I was wondering if you could write a litte more on this topic?
    I’d be very grateful if you could elaborate a
    little bit more. Many thanks!

  22. Hi! This is my first comment here so I just wanted
    to give a quick shout out and tell you I really
    enjoy reading your blog posts. Can you suggest any other blogs/websites/forums that deal with the same
    topics? Thanks a lot!

  23. I’m impressed, I have to admit. Seldom do
    I encounter a blog that’s both educative and interesting, and let me tell you, you have hit the nail on the head.
    The problem is something too few men and women are speaking intelligently about.
    Now i’m very happy that I stumbled across this in my search for something relating to this.

  24. This site was… how do you say it? Relevant!! Finally
    I’ve found something which helped me. Many thanks!

  25. natalielise says:

    Hi! I’ve been reading your site for a while now and finally got the bravery to go ahead and give you a shout out from
    Austin Tx! Just wanted to tell you keep up the great work!
    plenty of fish natalielise

  26. I think the admin of this site is in fact working hard for his website, since here every information is quality based
    information.

  27. I know this if off topic but I’m looking into starting
    my own blog and was wondering what all is required to get set up?
    I’m assuming having a blog like yours would cost a pretty
    penny? I’m not very internet savvy so I’m not 100% positive.
    Any suggestions or advice would be greatly appreciated.
    Many thanks

  28. Hey this is somewhat of off topic but I was wondering if blogs use WYSIWYG editors or if you have to manually code with HTML.
    I’m starting a blog soon but have no coding knowledge so I wanted to get guidance from someone with experience.
    Any help would be greatly appreciated!

  29. I know this website provides quality depending posts and other data, is there any other website which gives such
    things in quality?

  30. smore.com says:

    Simply desire to say your article is as astounding. The clearness in your post is simply cool and i can assume you’re an expert on this subject.
    Well with your permission let me to grab your feed
    to keep up to date with forthcoming post. Thanks a million and
    please keep up the enjoyable work. natalielise pof

  31. Paragraph writing is also a excitement, if you know after that you can write otherwise it is complicated to write.

  32. It’s an awesome paragraph designed for all the web viewers;
    they will get benefit from it I am sure.

  33. dating site says:

    Informative article, just what I needed.

  34. I visited multiple sites but the audio quality for audio songs existing
    at this website is in fact marvelous. natalielise pof

  35. I think that what you said made a ton of sense.
    But, think about this, what if you were to create a awesome
    title? I am not saying your content is not solid, however suppose
    you added something that makes people desire more? I mean Genentech
    to Highlight Actemra and Rituxan Data at EULAR Annual
    Congress – Global Genes is kinda boring. You should peek at Yahoo’s
    home page and note how they create news headlines to grab viewers to click.
    You might add a video or a pic or two to get readers interested about everything’ve written. Just my opinion, it might make your posts a little livelier.

  36. Hi there, just became aware of your blog through
    Google, and found that it is really informative. I’m
    going to watch out for brussels. I will be grateful if you
    continue this in future. Lots of people will be benefited from your writing.

    Cheers!

  37. I was suggested this web site by my cousin. I’m not sure
    whether this post is written by him as nobody else know such detailed about my trouble.
    You’re amazing! Thanks!

  38. Hurrah! After all I got a blog from where I can genuinely obtain helpful data concerning my study and knowledge.

  39. Heya i’m for the first time here. I found this board
    and I find It truly helpful & it helped me out much.
    I’m hoping to give something again and aid others like you
    helped me.

  40. Wow that was unusual. I just wrote an incredibly long comment but
    after I clicked submit my comment didn’t appear. Grrrr…
    well I’m not writing all that over again. Anyhow, just wanted
    to say excellent blog!

  41. Good day! This is my first visit to your blog!
    We are a team of volunteers and starting a new initiative in a community in the same niche.
    Your blog provided us useful information to work on.
    You have done a extraordinary job!

  42. Great article! This is the kind of information that are supposed to be shared around the net.
    Disgrace on Google for no longer positioning this submit upper!
    Come on over and seek advice from my site . Thanks
    =)

  43. I appreciate, lead to I discovered just what I was looking for.
    You have ended my 4 day lengthy hunt! God Bless you man. Have a great day.

    Bye

  44. Greetings! Quick question that’s entirely off
    topic. Do you know how to make your site mobile friendly?

    My blog looks weird when browsing from my iphone. I’m trying to find
    a theme or plugin that might be able to resolve this issue.
    If you have any recommendations, please share. Thank you!

  45. If you are going for best contents like me, only pay a quick visit this web
    site every day since it offers quality contents,
    thanks

  46. Normally I do not learn post on blogs, however I would like to say that this write-up very pressured me
    to take a look at and do it! Your writing
    taste has been surprised me. Thank you, very great post.

  47. Hi there to every one, the contents existing at this site are truly amazing for people
    knowledge, well, keep up the nice work fellows.

  48. I know this if off topic but I’m looking into starting my own blog and was curious what all is needed to get setup?
    I’m assuming having a blog like yours would cost a
    pretty penny? I’m not very internet savvy so I’m not 100% certain. Any suggestions
    or advice would be greatly appreciated. Many thanks

  49. Hi every one, here every one is sharing such familiarity, so it’s pleasant to read this
    weblog, and I used to pay a visit this blog all the time.

  50. Hey there! I know this is kinda off topic nevertheless I’d figured I’d ask.
    Would you be interested in trading links or maybe guest authoring a blog article or vice-versa?

    My site discusses a lot of the same topics as yours
    and I think we could greatly benefit from each other. If you happen to be interested feel free to shoot me an e-mail.
    I look forward to hearing from you! Wonderful blog by the way!

  51. A motivating discussion is definitely worth comment. There’s no doubt that that you need
    to write more about this subject, it may not be a
    taboo subject but usually people don’t speak about these issues.
    To the next! Best wishes!!

  52. Pretty section of content. I simply stumbled upon your
    weblog and in accession capital to say that I get in fact enjoyed account your weblog posts.
    Any way I will be subscribing on your feeds or even I fulfillment you access consistently
    fast.

  53. Thank you, I’ve recently been looking for info about this subject for ages and yours is the greatest I’ve
    found out till now. However, what concerning the bottom line?
    Are you certain about the source?

  54. I think this is one of the so much significant information for
    me. And i am glad studying your article. But wanna remark on some common things, The web site taste is perfect,
    the articles is in reality excellent : D. Excellent job, cheers

  55. Wonderful beat ! I wish to apprentice whilst you
    amend your web site, how can i subscribe for a weblog site?
    The account helped me a appropriate deal. I have been a little bit acquainted of this your broadcast provided bright clear idea

Leave a Reply

Your email address will not be published.

X